Latest Breaking News On - நீரோடை பார்மா - Page 12 : comparemela.com

Sensex, Nifty end almost flat; pharma shares climb

Benchmarks trade firm; Nifty above 14,700

The domestic barometers were trading firm in early afternoon trade. The Nifty index was trading tad above 14,700 mark. Pharma, realty and FMCG shares were in demand. At 12:20 IST, the barometer index, the S&P BSE Sensex, rose 179.11 points or 0.36% at 49,338.43. The Nifty 50 index gained 71 points or 0.49% at 14,708.80. In the broader market, the S&P BSE Mid-Cap index added 1.04% while the S&P BSE Small-Cap index rose 0.93%. The market breadth was strong. On the BSE, 1,713 shares rose and 960 shares fell. A total of 161 shares were unchanged. Derivatives: The NSE s India VIX, a gauge of market s expectation of volatility over the near term, fell 1.30% to 20.9375. The Nifty 29 April 2021 futures were trading at 14,788.95, at a premium of 80.15 points as compared with the spot at 14,708.80.

Madhya pradeshTilak nagarSun pharmaceutical industriesTilaknagar industriesMinistry of healthFamily welfareNifty pharmaTorrent pharmaPernod ricard indiaCapital marketமத்யா பிரதேஷ்திலக் நகர்சூரியன் மருந்து தொழில்கள்திலக்நகர் தொழில்கள்அமைச்சகம் ஆஃப் ஆரோக்கியம்குடும்பம் நலன்புரி

ChrysCapital announces investment in Corona Remedies

ChrysCapital announces investment in Corona Remedies By IANS | Published on Mon, Apr 5 2021 20:57 IST | 9 Views CFMA sees poetic justice for MF investors through 6 FTMF shut funds case in SC.. Image Source: IANS News New Delhi, April 5 : ChrysCapital, one of the leading private equity funds in India, has announced its investment in Corona Remedies Private Limited (Corona), one of the country s fastest growing pharmaceutical companies, by acquiring a 27 per cent stake through an entirely secondary deal. Commenting on the investment, Kshitij Sheth, Director, ChrysCapital, said, ChrysCapital is very excited to partner with Corona in its growth journey. The domestic pharmaceutical market is a large, attractive and resilient market with a healthy outlook. Corona is among the fastest growing companies in the Indian pharmaceutical market with presence in exciting therapeutic areas including cardiology, diabetology and gynaecology. ChrysCapital believes Corona

New delhiAnkur mehtaIntas pharmaZydus cadilaNirav mehtaShardul amarchand mangaldasKshitij shethCorona remedies private limitedFounder directorCapital advisorsVertices partnersMankind pharmaEris lifesciencesTorrent pharmaIpca labsCuratio healthcare

Sun Pharma: From Sun to Alkem, drug makers are spending big on data Here s why the government is loving it

Getty Images Synopsis Experts say the moves point to a larger strategy to digitise the supply chain, plug loopholes, promote transparency, and take healthcare to remote corners, as envisaged by the government’s National Digital Health Mission. Besides, setting up of a pan-India online pharmacy chain is also a distinct possibility. The Indian government and the pharmaceutical industry are forever at loggerheads. If the industry clamours against price caps on medicines, the government flashes the public-health card. If the industry pleads for tax incentives, the government buries those files. And it goes on. However, for a change, a consensus seems to be emerging on laying the foundations for an efficient and inclusive system that promises to deliver healthcare to the

Sun pharmaZydus cadilaTorrent pharmaசூரியன் பார்மாஜய்துச் காடிலாநீரோடை பார்மா

Nifty outlook & trading ideas by Gaurav Garg of CapitalVia Global Research

Nifty outlook & trading ideas by Gaurav Garg of CapitalVia Global Research
business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.

Biocon limited above rsNifty bankBiocon limitedTorrent pharmaGaurav gargCapitalvia global researchநிஃப்டி வங்கிபயோகான் வரையறுக்கப்பட்டவைநீரோடை பார்மாகௌராவ் கார்க்